Navigation Links
Groundbreaking MMRF CoMMpass Study(SM) Affirmed as Premier Genomics Data Set in Multiple Myeloma
Date:12/2/2016

NORWALK, Conn., Dec. 2, 2016 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) today announced that 19 research presentations from the MMRF CoMMpass StudySM—the largest and most comprehensive study driving new genomic insights and accelerating precision medicine in multiple myeloma—will be presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego from December 3-6. The new analyses are helping to optimize treatment strategies, as well as identify pathways and targets for new drug development.

Findings will also be presented by the Multiple Myeloma Research Consortium (MMRC) that demonstrate the safety and efficacy of four novel treatments.

"Data sharing and collaboration are vital to driving innovation and accelerating new and better treatments for patients," said Paul Giusti, President and Chief Executive Officer of the MMRF. "We are proud that the MMRF CoMMpass Study is now the largest genomics data set in all of cancer, and grateful to our partners and the patients who made this possible. The exciting data presented at the ASH Annual Meeting validate our collaborative, visionary model to speeding the development of precision medicine approaches that will be critical to improving patient outcomes."

Among the analyses from the MMRF CoMMpass Study are four presentations helping to define which patients are at a higher risk of early relapse, defined as less than 18 months following first-line therapy. Additionally, these analyses uncovered that some of the identified genetic defects associated with early relapse could be treated with drugs currently being used for other cancers, while others are new targets for the next generation of anti-myeloma drugs.  

Another analysis from the MMRF CoMMpass Study identified that patients with a high level of genetic mutations also had high levels of neoantigens (potential natural targets of the immune system), and suggested that those patients had inferior outcomes when treated with the current standard of care. However, there are now novel agents able to stimulate the immune system and these findings offer a promising basis for pursuing tailored immunotherapeutic approaches for multiple myeloma, especially for those patients with a higher mutational burden.

Additionally, new data being presented at ASH from eight trials led by the MMRC have demonstrated initial efficacy and safety of four new therapies, as well as the encouraging activity of novel combination therapies and treatments across various stages of multiple myeloma. The MMRC is the MMRF's clinical network of centers of excellence, consisting of 22 academic institutions.

"Despite advancements in treatment, an estimated 12,650 Americans die each year from multiple myeloma," said Dr. Sagar Lonial, Chair Department of Hematology and Medical Oncology and CMO Winship Cancer Institute of Emory University, Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and Global Lead Investigator for the MMRF CoMMpass Study. "The MMRF has made an unprecedented investment to advance the understanding of multiple myeloma at a genomic level and accelerate precision medicine. We reject the idea that progress cannot be made and are committed to ensuring all patients have options available when they need them based on science and data."

Specific results from the MMRC-led trials include:

  • A phase II trial showing that a combination of EMPLICITITM (elotuzumab), REVLIMID® (lenalidomide) and dexamethasone for the treatment of high-risk patients with smoldering myeloma delayed progression to active multiple myeloma. (Abstract # 976)
  • A phase II study evaluating extended treatment of patients undergoing autologous stem cell transplant with the combination of KYPROLIS® (carfilzomib), REVLIMID® (lenalidomide) and dexamethasone showed improvements in disease progression and survival. (Abstract # 675)
  • Five early-phase studies evaluated 4 new compounds, selinexor, isatuximab, marizomib, and ventoclax, all showing promising efficacy in patients that had previously received many lines of therapy.

Presentations from the MMRF CoMMpass Study and MMRC include:

MMRF CoMMpass Study Abstracts:

Saturday, December 3, 2016: 9:30 AM-11:00 AM, Grand Hall D (Manchester Grand Hyatt San Diego)

  • Abstract # 120: Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial

Saturday, December 3, 2016: 2:00 PM-3:30 PM, Grand Hall D (Manchester Grand Hyatt San Diego)

  • Abstract # 193: Correlation Between Somatic Mutation Burden, Neoantigen Load and Progression Free Survival in Multiple Myeloma: Analysis of MMRF CoMMpass Study
  • Abstract # 194: Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the MMRF CoMMpass Study

Saturday, December 3, 2016: 5:30 PM-7:30 PM, Hall GH (San Diego Convention Center)

  • Abstract # 2079: Prognostic Implication of Somatic Mutations by Next Generation Sequencing: An Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients
  • Abstract # 2350: The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials
  • Abstract # 2084: Uncovering Clonal and Subclonal Druggable Targets in Multiple Myeloma Using Omic Data
  • Abstract # 2099: Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients by Computational Mapping of Protein Network Disturbances
  • Abstract # 2108: B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma
  • Abstract # 2349: Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

Sunday, December 4, 2016: 9:30 AM-11:00 AM, Grand Hall D (Manchester Grand Hyatt San Diego)

  • Abstract # 355: Complementary Activation of Ccnd, MYC, RAS and NFkB by Mutations in Multiple Myeloma
  • Abstract # 357: Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification

Sunday, December 4, 2016: 12:00 PM-1:30 PM, Grand Hall D (Manchester Grand Hyatt San Diego)

  • Abstract # 374: A Comparison of Clinical FISH and Sequencing Based FISH Estimates in Multiple Myeloma: An MMRF CoMMpass Analysis

Sunday, December 4, 2016: 6:00 PM-8:00 PM, Hall GH (San Diego Convention Center)

  • Abstract # 3285: Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Risk Gene Signature
  • Abstract # 3279: Reliability of Myeloma Model Systems: KP-6 Is a Novel Hyperdiploid Cell Line

Monday, December 5, 2016: 10:30 AM-12:00 PM, Grand Hall D (Manchester Grand Hyatt San Diego)

  • Abstract # 802: Network Modeling Reveals CDC42BPA and CLEC11A as Novel Driver Genes of t(4; 14) Multiple Myeloma

Monday, December 5, 2016: 6:00 PM-8:00 PM, Hall GH (San Diego Convention Center)

  • Abstract # 4432: Genomic Variability in Multiple Myeloma (MM) Patients by Race: An Analysis of the Publically Available MMRF CoMMpass Study Database
  • Abstract # 4502: Practice Patterns in Newly Diagnosed Multiple Myeloma in the Prospective Observational CoMMpass Trial
  • Abstract # 4406: Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response
  • Abstract # 4423: A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13)

MMRC Study Abstracts:

Saturday, December 3, 2016: 5:30 PM-7:30 PM, Hall GH (San Diego Convention Center)

  • Abstract # 2111: Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Sunday, December 4, 2016: 4:30 PM-6:00 PM, Hall AB (San Diego Convention Center)

  • Abstract # 488: Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Sunday, December 4, 2016: 6:00 PM-8:00 PM, Hall GH (San Diego Convention Center)

  • Abstract # 3326: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study
  • Abstract # 3316: A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Monday, December 5, 2016: 7:00 AM-8:30 AM, Seaport Ballroom DE (Manchester Grand Hyatt San Diego)

  • Abstract # 675: Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Monday, December 5, 2016: 2:45 PM-4:15 PM, Seaport Ballroom BC (Manchester Grand Hyatt San Diego)

  • Abstract # 973: Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
  • Abstract# 976: Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

About the MMRF CoMMpass StudySM 
The MMRF CoMMpass Study is a longitudinal study of patients with newly diagnosed active multiple myeloma. The goal is to map the genomic profile of each patient to clinical outcomes to develop a more complete understanding of patient responses to treatments. A cornerstone of the MMRF's Personalized Medicine Initiative, the study is collecting and analyzing tissue samples, clinical data and genetic information from 1,000 newly diagnosed multiple myeloma patients for at least nine years.

The study is designed to show which treatments are used most often as first and subsequent lines of therapy, and to correlate this information with critical therapeutic response criteria including best responses achieved, overall survival, time to disease progression and quality of life measures. Each patient enrolled in the study is required to receive an approved proteasome inhibitor, immunomodulatory drug or both.

The MMRF CoMMpass Study opened in July of 2011 and now includes 1,000 patients from more than 100 sites in the United States, Canada and European Union. Data from the MMRF CoMMpass Study is made available to researchers via the MMRF's Researcher Gateway (http://research.themmrf.org), an online, open-access portal designed to make key genomic and clinical data available for additional study. The MMRF CoMMpass Study is being supported through a public-private partnership of patient donors and industry partners, including Takeda Oncology, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc. and Janssen Diagnostics. Additional collaborating research partners include the Translational Genomics Research Institute, Van Andel Research Institute and GNS Healthcare.

Please visit www.themmrf.org/research-partners/the-commpass-study to learn more about the study.

About Multiple Myeloma
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,330 adults (17,900 men and 12,430 women) in the United States will be diagnosed with MM in 2016 and an estimated 12,650 people are predicted to die from the disease. The five-year survival rate for MM is approximately 47%, versus 31% in 1999.

About the Multiple Myeloma Research Foundation (MMRF)
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers.  The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts.  Since its inception, the organization has raised over $330 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.

About the Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509 (a)(3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 22 member institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center Home, Beth Israel Deaconess, Brigham and Women's Hospital, Mayo Clinic (Jacksonville, Rochester and Scottsdale), Baylor Charles A. Sammons Cancer Center at Dallas, Barbara Ann Karmanos Cancer Institute, City of Hope, Emory University's Winship Cancer Institute, Levine Cancer Institute, The John Theurer Cancer Center at Hackensack University Medical Center, Mount Sinai School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California, San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists and Washington University in St. Louis.

The MMRC is the only consortium in multiple myeloma to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.

Media Contacts
Sharon Saias
Vice President, Marketing & Communications
Multiple Myeloma Research Foundation
203-652-0211
saiass@themmrf.org

Logo - http://photos.prnewswire.com/prnh/20161202/445114LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/groundbreaking-mmrf-commpass-studysm-affirmed-as-premier-genomics-data-set-in-multiple-myeloma-300372253.html


'/>"/>
SOURCE Multiple Myeloma Research Foundation
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. DryLet to Showcase Patented ManureMagic™ and Its Groundbreaking Purdue University Study Results at the 2016 World Pork Expo, June 8-10 in Des Moines, Iowa
2. Serenium Announces a Groundbreaking Biomarker Development Program with a Global Strategic Partner to Accelerate Early Identification of People at Risk for Chronic Disease
3. Vortex Biosciences Inventor Receives Presidential Award for Research Leading to Groundbreaking "Liquid Biopsy" Technique
4. Health Connexions & Ascentii Announce a RoleFit Survey™ Global Expansion: A Groundbreaking Innovation for Employers to Identify the Best-Matched “A-List” of Candidates
5. What Gut Bacteria Can Teach Us About Eating Disorders: uBiome and University of North Carolina Launch Groundbreaking Study
6. Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth
7. uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research
8. Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas
9. SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine
10. Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida
11. DNA Spectrum to Debut Groundbreaking myDNA Fitness Program and gFit Goals at The 2015 Los Angeles Fit Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... According to a recent report ... do not have negative short- or long-term effects on benthic communities. , ... (PCBs) located at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in ...
(Date:6/26/2017)... ... 26, 2017 , ... Third Wave Bioactives, LLC announces the addition of Brett ... new business development and ensuring quality customer experience. , Brett brings to ... in technical, marketing and sales roles. “Brett’s background working with customers and eye for ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... solutions provider, announced the latest version of LimitLIS®, its rapidly growing Laboratory Information ... speed up user adoption, ensure installation integrity, and provide more customization options. Each ...
(Date:6/22/2017)... NC (PRWEB) , ... June 21, 2017 , ... ... for attracting and hiring top executive talent in the life sciences industry, today ... and Manufacturing company. The partnership takes full advantage of Beaker’s expertise in ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):